Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration
NCT: NCT02725762 · COMPLETED
NCT IDNCT02725762
StatusCOMPLETED
Start Date2016-03
Completion2018-07
SponsorLumiThera, Inc. (INDUSTRY)
First posted
Last updated
Brief Summary
The purpose of this research study is to determine if photobiomodulation is an effective treatment of Dry Age-Related Macular Degeneration (AMD) and vision loss associated with the disease.
Frequently Asked Questions
What is Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration?
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration is a clinical trial registered under NCT02725762. Current status: COMPLETED.
What is the status of NCT02725762?
The current status of NCT02725762 (Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration) is: COMPLETED.
When did Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration start?
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration started on 2016-03.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.